VERTEX PHARMACEUTICALS INC / MA Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.

Discontinued › Income Statement › Earnings Per Share

us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2013-05-08

VERTEX PHARMACEUTICALS INC / MA incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2013-03-31 was 0.00 shares, a 100.00% decline year-over-year.
VERTEX PHARMACEUTICALS INC / MA incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2012-03-31 was 8.89M shares.
VERTEX PHARMACEUTICALS INC / MA incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2011-09-30 was 8.89M shares.

Period end	Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month
2013-03-31	0.00 shares 10-Q · filed 2013-05-08
2012-03-31	8.89M shares 10-Q · filed 2013-05-08
2011-09-30	8.89M shares 10-Q · filed 2012-11-06

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
PFIZER INC (PFE)	United States	$162.042B	31.94
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64